Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

Sung Hee Choi; Jay Thomas Myers; Suzanne Louise Tomchuck; Melissa Bonner; Saada Eid; Daniel Tyler Kingsley; Kristen Ashley VanHeyst; Seong-Jin Kim; Byung-Gyu Kim; Alex Yee-Chen Huang

doi:10.1002/cac2.12589

Cancer Communications ›› 2024, Vol. 44 ›› Issue (08) : 884-888. DOI: 10.1002/cac2.12589

LETTER TO THE JOURNAL

Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Sung Hee Choi, Jay Thomas Myers, Suzanne Louise Tomchuck, Melissa Bonner, Saada Eid, Daniel Tyler Kingsley, Kristen Ashley VanHeyst, Seong-Jin Kim, Byung-Gyu Kim, Alex Yee-Chen Huang. Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity. Cancer Communications, 2024, 44(08): 884‒888 https://doi.org/10.1002/cac2.12589

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	PetrilliAS, de Camargo B, FilhoVO, BrunieraP, Brunetto AL, Jesus-GarciaR. et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006; 24(7): 1161–1168. CrossRef Google scholar

[2]	XuS, YangS, SunG, HuangW, ZhangY. Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma. DNA Cell Biol. 2014; 33(11): 802–806. CrossRef Google scholar

[3]	KimBG, MalekE, ChoiSH, Ignatz-Hoover JJ. DriscollJJ. Novel therapies emerging in oncology to target the TGF-beta pathway. J Hematol Oncol. 2021; 14(1): 55. CrossRef Google scholar

[4]	SonJY, ParkSY, KimSJ, Lee SJ, ParkSA, KimMJ, et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther. 2014; 13(7): 1704–1716. CrossRef Google scholar

[5]	de Oliveira RodriguesMT, Pereira da SilvaL, Pogue RE, de CarvalhoJL, MotoyamaAB, de Alencar EST, et al. Induced resistance to ifosfamide in osteosarcoma cells suggests a more aggressive tumor profile. Biochem Biophys Rep. 2022; 32: 101357. CrossRef Google scholar

[6]	Garces de Los Fayos AlonsoI, LiangHC, TurnerSD, LaggerS, Merkel O, KennerL. The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas. Cancers (Basel). 2018; 10(4): 93. CrossRef Google scholar

[7]	ChenD, ZhaoZ, HuangZ, Chen DC, ZhuXX, WangYZ, et al. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018; 6: 11. CrossRef Google scholar

[8]	WongDP, FritzCE, FeinbergD, Huang AY, ParameswaranR. p35 is a Crucial Player in NK-cell Cytotoxicity and TGFbeta-mediated NK-cell Dysfunction. Cancer Res Commun. 2023; 3(5): 793–806. CrossRef Google scholar

[9]	YangH, ZhaoL, ZhangY, Li FF. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Cancer Med. 2021; 10(16): 5696–5711. CrossRef Google scholar

[10]	BoyeK, LonghiA, GurenT, Lorenz S, NaessS, PieriniM, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021; 70(9): 2617–2624. CrossRef Google scholar